Thymus alterations and susceptibility to immune checkpoint inhibitor myocarditis
- PMID: 37884625
- DOI: 10.1038/s41591-023-02591-2
Thymus alterations and susceptibility to immune checkpoint inhibitor myocarditis
Erratum in
-
Author Correction: Thymus alterations and susceptibility to immune checkpoint inhibitor myocarditis.Nat Med. 2023 Dec;29(12):3268. doi: 10.1038/s41591-023-02690-0. Nat Med. 2023. PMID: 38012317 No abstract available.
-
Publisher Correction: Thymus alterations and susceptibility to immune checkpoint inhibitor myocarditis.Nat Med. 2024 Mar;30(3):910. doi: 10.1038/s41591-023-02771-0. Nat Med. 2024. PMID: 38172633 No abstract available.
Abstract
Immune checkpoint inhibitors (ICI) have transformed the therapeutic landscape in oncology. However, ICI can induce uncommon life-threatening autoimmune T-cell-mediated myotoxicities, including myocarditis and myositis. The thymus plays a critical role in T cell maturation. Here we demonstrate that thymic alterations are associated with increased incidence and severity of ICI myotoxicities. First, using the international pharmacovigilance database VigiBase, the Assistance Publique Hôpitaux de Paris-Sorbonne University data warehouse (Paris, France) and a meta-analysis of clinical trials, we show that ICI treatment of thymic epithelial tumors (TET, and particularly thymoma) was more frequently associated with ICI myotoxicities than other ICI-treated cancers. Second, in an international ICI myocarditis registry, we established that myocarditis occurred earlier after ICI initiation in patients with TET (including active or prior history of TET) compared to other cancers and was more severe in terms of life-threatening arrythmias and concurrent myositis, leading to respiratory muscle failure and death. Lastly, we show that presence of anti-acetylcholine-receptor antibodies (a biological proxy of thymic-associated autoimmunity) was more prevalent in patients with ICI myocarditis than in ICI-treated control patients. Altogether, our results highlight that thymic alterations are associated with incidence and seriousness of ICI myotoxicities. Clinico-radio-biological workup evaluating the thymus may help in predicting ICI myotoxicities.
© 2023. The Author(s), under exclusive licence to Springer Nature America, Inc.
Similar articles
-
[Clinical features of immune checkpoint inhibitor-related myositis in patients with urological cancer].Beijing Da Xue Xue Bao Yi Xue Ban. 2022 Aug 18;54(4):644-651. doi: 10.19723/j.issn.1671-167X.2022.04.010. Beijing Da Xue Xue Bao Yi Xue Ban. 2022. PMID: 35950386 Free PMC article. Chinese.
-
Incidence and Distinct Features of Immune Checkpoint Inhibitor-Related Myositis From Idiopathic Inflammatory Myositis: A Single-Center Experience With Systematic Literature Review and Meta-Analysis.Front Immunol. 2021 Dec 6;12:803410. doi: 10.3389/fimmu.2021.803410. eCollection 2021. Front Immunol. 2021. PMID: 34938300 Free PMC article.
-
Abatacept/Ruxolitinib and Screening for Concomitant Respiratory Muscle Failure to Mitigate Fatality of Immune-Checkpoint Inhibitor Myocarditis.Cancer Discov. 2023 May 4;13(5):1100-1115. doi: 10.1158/2159-8290.CD-22-1180. Cancer Discov. 2023. PMID: 36815259
-
Immune Checkpoint Inhibitor-Induced Myositis: a Case Report and Literature Review.Curr Rheumatol Rep. 2019 Feb 21;21(4):10. doi: 10.1007/s11926-019-0811-3. Curr Rheumatol Rep. 2019. PMID: 30790071 Review.
-
Pembrolizumab-Induced Fatal Myasthenia, Myocarditis, and Myositis in a Patient with Metastatic Melanoma: Autopsy, Histological, and Immunohistochemical Findings-A Case Report and Literature Review.Int J Mol Sci. 2023 Jun 30;24(13):10919. doi: 10.3390/ijms241310919. Int J Mol Sci. 2023. PMID: 37446095 Free PMC article. Review.
Cited by
-
Global burden of vaccine-associated Guillain-Barré syndrome over 170 countries from 1967 to 2023.Sci Rep. 2024 Oct 19;14(1):24561. doi: 10.1038/s41598-024-74729-2. Sci Rep. 2024. PMID: 39427003 Free PMC article.
-
Autoantibody profiling of patients with immune checkpoint inhibitor-associated myocarditis: a pilot study.Front Immunol. 2024 Sep 11;15:1423622. doi: 10.3389/fimmu.2024.1423622. eCollection 2024. Front Immunol. 2024. PMID: 39324142 Free PMC article.
-
Comparative analysis of adverse event risks in breast cancer patients receiving pembrolizumab combined with paclitaxel versus paclitaxel monotherapy: insights from the FAERS database.Front Pharmacol. 2024 Aug 21;15:1345671. doi: 10.3389/fphar.2024.1345671. eCollection 2024. Front Pharmacol. 2024. PMID: 39234109 Free PMC article.
-
Immuno-related cardio-vascular adverse events associated with immuno-oncological treatments: an under-estimated threat for cancer patients.Basic Res Cardiol. 2024 Sep 3. doi: 10.1007/s00395-024-01077-7. Online ahead of print. Basic Res Cardiol. 2024. PMID: 39225869 Review.
-
Gasdermin-E-mediated pyroptosis drives immune checkpoint inhibitor-associated myocarditis via cGAS-STING activation.Nat Commun. 2024 Aug 5;15(1):6640. doi: 10.1038/s41467-024-50996-5. Nat Commun. 2024. PMID: 39103324 Free PMC article.
References
Publication types
MeSH terms
Substances
Grants and funding
- CIC-1901/Direction Générale de l'offre de Soins (DGOS)
- R01HL141466/Foundation for the National Institutes of Health (Foundation for the National Institutes of Health, Inc.)
- R01HL155990/Foundation for the National Institutes of Health (Foundation for the National Institutes of Health, Inc.)
- R01HL156021/Foundation for the National Institutes of Health (Foundation for the National Institutes of Health, Inc.)
- R01HL160688/Foundation for the National Institutes of Health (Foundation for the National Institutes of Health, Inc.)
- R01HL153384/Foundation for the National Institutes of Health (Foundation for the National Institutes of Health, Inc.)
- R01-DK128012/Foundation for the National Institutes of Health (Foundation for the National Institutes of Health, Inc.)
- LE3570/2-1; 3570/3-1/Deutsche Forschungsgemeinschaft (German Research Foundation)
- 01KC2006B/Bundesministerium für Bildung und Forschung (Federal Ministry of Education and Research)
LinkOut - more resources
Full Text Sources
Medical